RT Journal Article
SR Electronic
T1 Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 443
OP 451
DO 10.3949/ccjm.80a.13025
VO 80
IS 7
A1 Fawole, Adewale
A1 Daw, Hamed A.
A1 Crowther, Mark A.
YR 2013
UL http://www.ccjm.org/content/80/7/443.abstract
AB The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. Management requires careful adherence to first principles of bleeding care. Unapproved and untested reversal strategies may be required in patients with life-threatening bleeding.